Details of the Drug Combination

General Information of Drug Combination (ID: DCX1HFP)

Drug Combination Name
Sodium stibogluconate Interferon Alfa-2b
Indication
Disease Entry Status REF
Advanced Cancer Phase 1 [1]
Component Drugs Sodium stibogluconate   DMH5MVE Interferon Alfa-2b   DMWCQP4
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sodium stibogluconate
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [2]
Leishmaniasis 1F54 Approved [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Sodium stibogluconate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leishmania DNA topoisomerase I (Leishm TOP1) TTNJKC3 Q9NJG8_LEIDO Modulator [4]
------------------------------------------------------------------------------------
Sodium stibogluconate Interacts with 13 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [6]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Expression [6]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [6]
Erythropoietin (EPO) OTZ90CN4 EPO_HUMAN Decreases Expression [7]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [6]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Increases Expression [8]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [6]
Interferon gamma receptor 1 (IFNGR1) OTCTQBWW INGR1_HUMAN Increases Expression [9]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Decreases Expression [10]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Decreases Expression [10]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Expression [6]
Tyrosine-protein phosphatase non-receptor type 6 (PTPN6) OT33XNZM PTN6_HUMAN Decreases Activity [8]
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Decreases Expression [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DOT(s)
Indication(s) of Interferon Alfa-2b
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [5]
Interferon Alfa-2b Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Interferon-alpha 2 (IFNA2) TTSIUJ9 IFNA2_HUMAN Modulator [13]
------------------------------------------------------------------------------------
Interferon Alfa-2b Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Increases Expression [12]
Interferon-induced, double-stranded RNA-activated protein kinase (EIF2AK2) OT8DXMS3 E2AK2_HUMAN Increases Expression [12]
Tyrosine-protein kinase JAK1 (JAK1) OT0X3D17 JAK1_HUMAN Increases Expression [12]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Increases Phosphorylation [12]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Increases Expression [12]
Signal transducer and activator of transcription 2 (STAT2) OTO9G2RZ STAT2_HUMAN Increases Phosphorylation [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 ClinicalTrials.gov (NCT00629200) Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
2 Perspectives of antimony compounds in oncology. Acta Pharmacol Sin. 2008 Aug;29(8):881-90.
3 Leishmaniasis in Norway. Tidsskr Nor Laegeforen. 2021 Feb 22;141(3).
4 Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused by Leishmania tropica: interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major regulatory factors. Immunology. 2010 Jun;130(2):193-201. doi: 10.1111/j.1365-2567.2009.03223.x. Epub 2010 Jan 22.
7 Serum erythropoietin concentration in anaemia of visceral leishmaniasis (kala-azar) before and during antimonial therapy. Br J Haematol. 1998 Mar;100(4):720-4. doi: 10.1046/j.1365-2141.1998.00624.x.
8 Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro. Leukemia. 2002 Nov;16(11):2285-91. doi: 10.1038/sj.leu.2402692.
9 Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells. Ann Trop Med Parasitol. 2003 Apr;97(3):245-57. doi: 10.1179/000349803235001714.
10 Soluble receptors for tumor necrosis factor as markers of disease activity in visceral leishmaniasis. J Infect Dis. 1995 Feb;171(2):498-501. doi: 10.1093/infdis/171.2.498.
11 SHP-1 is directly activated by the aryl hydrocarbon receptor and regulates BCL-6 in the presence of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol Appl Pharmacol. 2016 Nov 1;310:41-50. doi: 10.1016/j.taap.2016.08.014. Epub 2016 Aug 18.
12 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon / by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells. Toxicol Appl Pharmacol. 2017 Dec 1;336:31-39. doi: 10.1016/j.taap.2017.10.004. Epub 2017 Oct 12.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.